Assessing Investigational CT1812’s Impact on Tau, Amyloid, and Neurodegeneration: Mary Hamby, PhD
Marco Meglio
The vice president of research at Cognition Therapeutics gave clinical insight on several new analyses covering CT1812, an orally delivered small molecule oligomer antagonist, in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]
WATCH TIME: 5 minutes
"Seeing CT1812’s impact across multiple biomarkers, not just one, is very encouraging—it reinforces the potential for real clinical benefit in Alzheimer treatment."
The SHINE study (NCT03507790) is a double-blind, placebo-controlled phase 2 signal-finding trial that enrolled 153 adults with mild-to-moderate Alzheimer disease (AD) who were evenly randomized to either placebo or one of 2 doses of CT1812 (100 mg or 300 mg), which was taken orally for 6 months. Supported by 2 grant awards from the National Institute on Aging, the study used safety and tolerability as the primary end point, with secondary end points that included the Alzheimer’s Disease Assessment Cognitive subscale (ADAS-Cog11), and exploratory measures such as the Mini-Mental State Exam, ADAS-Cog13, ADCS-ADL, and Clinical Global Impression of Change.
At the
During the conference, Hamby, vice president of research at Cognition Therapeutics, sat down with NeurologyLive® to discuss the data, highlighting the drug’s promising cognitive and biomarker effects. In addition, she gave clinical insights on the plasma biomarker findings, noting that while the intent-to-treat population showed little change, the low tau group exhibited significant reductions in notable biomarkers of neurodegenerative disease. Furthermore, she provided additional clarity on the exploratory proteomic analysis, emphasizing how these findings advance a biomarker-driven approach to AD trials.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
